News for Eli Lilly and Company (LLY.MX)

PR NewswireDUBLIN, July 10, 2025 ”“ Selection Follows Robust Succession Process Led by the Board ”“”“ Bruce Cozadd to Retire as CEO and Remain Chairpers

Eli Lilly (LLY) has received FDA approval for a revised dosing schedule for Kisunla (donanemab-azbt) aimed at improving safety in Alzheimer's treatment.

Eli Lilly and Company (NYSE:LLY) is one of the 10 Best Non-Tech Stocks to Buy and Hold For 3 Years. On June 22, Eli Lilly and Company (NYSE:LLY) announced new results for its once-weekly insulin, Efsitora alfa. The drug is being tested for adults with type 2 diabetes. The company released results for QWINT-1, QWINT-3, and […]

In eight tumors where patients failed immune checkpoint inhibitor (ICI) treatment, Plinabulin + radiation + PD-1 inhibitors demonstrated an overall response rat

Eli Lilly and Company (NYSE:LLY) is one of the 13 best blue-chip stocks to buy, according to analysts. On June 30, RBC Capital Markets reiterated that the company’s upcoming TRAILBLAZER-3 trial data on Kisunla could unlock significant value in the Alzheimer’s treatment market. The research firm is optimistic that the trial will deliver positive results, […]

Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.

Eli Lilly and Company (NYSE:LLY) is among the Goldman Sachs Stock Portfolio: 10 Large-Cap Stocks To Buy.

British HealthTech startup Laverock Therapeutics, a gene control company focused on the development of disease-responsive advanced therapies, announced

SAN FRANCISCO and SUZHOU, China, June 30, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ('Innovent') (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology, and other major diseases, held its Oncology R&D Day, unveiling its forward-looking strategy centered on dual innovation in next-generation immuno-oncology (IO) and antibody-drug conjugate (ADC) technologies. This strategic focus aims to redefine the standards of cancer treatment and propel Innovent toward becoming a global, premier biopharmaceutical leader. The event drew over 500 participants, including leading oncology key opinion leaders (KOLs), principal investigators, analysts, and global investors, signaling strong engagement with Innovent's transformative vision for the future of oncology.

Eli Lilly and Company (NYSE:LLY) is one of the 12 stocks that will make you rich in 10 years. On June 23, Truist Securities reiterated its “Buy” rating on Eli Lilly stock. The firm also maintained the price target of $1,038.00. Truist’s move followed Eli Lilly’s presentation at the American Diabetes Association (ADA) 85th Annual […]

PR NewswireNEW YORK, June 27, 2025 NEW YORK, June 27, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following co

PR NewswireSAN FRANCISCO and SUZHOU, China, June 27, 2025 SAN FRANCISCO and SUZHOU, China, June 27, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innoven

Concentra® Group Holdings Parent, Inc. (”œConcentra”) (NYSE: CON), today announced the appointment of Vipin Gopal and Brigid Bonner to the Concentra Board

Eli Lilly's Mounjaro diabetes and weight-loss drug approved in India in KwikPen device, offering personalized treatment options.

Eli Lilly and Company (NYSE:LLY) is one of the most frequently discussed stocks on Cramer’s morning show.

Eli Lilly and Company (NYSE:LLY) is one of the best Fortune 500 stocks to buy according to billionaires. On June 20, Eli Lilly reported a positive reception for its blockbuster drug Mounjaro in India and is now prioritizing meeting the demand in the world’s most populous country, with a population of 1.4 billion. Eli Lilly […]

PR NewswireINDIANAPOLIS, June 23, 2025 INDIANAPOLIS, June 23, 2025 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared

Eli Lilly (LLY) announces a third-quarter 2025 dividend of $1.50 per share. Dividend is payable on September 10, 2025, to shareholders recorded by Augus

Baron Funds, an investment management company, released its “Baron Fifth Avenue Growth Fund” first quarter 2025 investor letter. A copy of the letter can be downloaded here.